Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Biological sex defines regulatory T-cell reprogramming trajectories in immune-related adverse events and autoimmunity

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 and CTLA-4 pathways have revolutionized cancer therapy but are frequently associated with immune-related adverse events (irAEs), i.e. inflammatory toxicities that resemble classical autoimmune diseases and reflect disruption of peripheral tolerance. Reg...

G. Kontogianni, P. Kouzis, H. Gogas et al. · 0 citations
Review Open access Sep 2026

Targeting the Untargeted: Emerging Targeted Therapies in Metastatic Melanoma Beyond BRAF/MEK Inhibitors.

The therapeutic landscape of advanced melanoma has been transformed by immune checkpoint inhibitors and BRAF/MEK inhibitors, resulting in substantial improvements in response rates and overall survival. However, both primary and acquired resistance remain frequent, commonly driven by MAPK pathway reactivation and activ...

Marianna Dimitrakopoulou, C. Theocharopoulos, Aikaterini Katsandri et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.